Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 8, 2012 - Issue 2
Submit an article Journal homepage
733
Views
68
CrossRef citations to date
0
Altmetric
Drug Profile

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

Bruno P Imbimbo Research and Development Department, Chiesi Farmaceutici, Parma, Italy. [email protected]; Research and Development Department, Chiesi Farmaceutici, Parma, Italy. [email protected]
,
Simone Ottonello Department of Biochemistry and Molecular Biology, University of Parma, Italy; Department of Biochemistry and Molecular Biology, University of Parma, Italy
,
Vincenza Frisardi Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy
,
Vincenzo Solfrizzi Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy; Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy
,
Antonio Greco Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy
,
Davide Seripa Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy
,
Alberto Pilotto Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Geriatrics Unit, Azienda ULSS 16 Padova, S Antonio Hospital, Padova, Italy; Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Geriatrics Unit, Azienda ULSS 16 Padova, S Antonio Hospital, Padova, Italy
&
Francesco Panza Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy; Department of Medical Sciences, Geriatric Unit and Gerontology – Geriatrics Research Laboratory, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, Foggia, Italy
 show all
Pages 135-149 | Published online: 10 Jan 2014

Citations (68)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Yang Xie, Yan Wang, Shangfei Jiang, Xiaohong Xiang, Jianhua Wang & Linhong Ning. (2022) Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein. Journal of Drug Targeting 30:3, pages 259-268.
Read now
Madia Lozupone, Vincenzo Solfrizzi, Francesca D’Urso, Ilaria Di Gioia, Rodolfo Sardone, Vittorio Dibello, Roberta Stallone, Angelo Liguori, Chiara Ciritella, Antonio Daniele, Antonello Bellomo, Davide Seripa & Francesco Panza. (2020) Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs 25:3, pages 319-335.
Read now
Justin L. Hoskin, Marwan Noel Sabbagh, Yazan Al-Hasan & Boris Decourt. (2019) Tau immunotherapies for Alzheimer’s disease. Expert Opinion on Investigational Drugs 28:6, pages 545-554.
Read now
Francesco Panza, Davide Seripa, Madia Lozupone, Vincenzo Solfrizzi, Bruno P. Imbimbo, Maria Rosaria Barulli, Rosanna Tortelli, Rosa Capozzo, Paola Bisceglia, Andrea Dimitri, Roberta Stallone, Vittorio Dibello, Nicola Quaranta, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2018) The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy 18:1, pages 25-35.
Read now
Francesco Panza, Davide Seripa, Vincenzo Solfrizzi, Bruno P. Imbimbo, Madia Lozupone, Antonio Leo, Rodolfo Sardone, Gaetano Gagliardi, Lucia Lofano, Bianca C. Creanza, Paola Bisceglia, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2016) Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opinion on Emerging Drugs 21:4, pages 377-391.
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo & Giancarlo Logroscino. (2014) Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?. Expert Opinion on Biological Therapy 14:10, pages 1465-1476.
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Michele Giannini, Andrea Santamato, Davide Seripa & Giancarlo Logroscino. (2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 14:9, pages 973-986.
Read now
Camryn Berk, Gaurav Paul & Marwan Sabbagh. (2014) Investigational drugs in Alzheimer's disease: current progress. Expert Opinion on Investigational Drugs 23:6, pages 837-846.
Read now
Hayk Davtyan, Andrew Bacon, Irina Petrushina, Karen Zagorski, David H Cribbs, Anahit Ghochikyan & Michael G Agadjanyan. (2014) Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines. Human Vaccines & Immunotherapeutics 10:5, pages 1248-1255.
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Rosanna Tortelli, Andrea Santamato & Giancarlo Logroscino. (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology 10:3, pages 405-419.
Read now
Walter J Lukiw. (2012) Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert Opinion on Emerging Drugs 17:1, pages 43-60.
Read now

Articles from other publishers (57)

Reisa A. SperlingMichael C. DonohueRema RamanMichael S. RafiiKeith JohnsonColin L. MastersChristopher H. van Dyck, Takeshi IwatsuboGad A. MarshallRoy YaariMichele ManciniKaren C. HoldridgeMichael CaseJohn R. SimsPaul S. Aisen. (2023) Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal of Medicine.
Crossref
Michael Kunle Ajenikoko, Abayomi Oyeyemi Ajagbe, Oluwanisola Akanji Onigbinde, Akeem Ayodeji Okesina & Ahmad Adekilekun Tijani. (2023) Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction. IBRO Neuroscience Reports 14, pages 64-76.
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Nastaran Karimi, Feyza Bayram Çatak, Ebru Arslan, Amene Saghazadeh & Nima Rezaei. (2022) Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy. International Immunopharmacology 113, pages 109445.
Crossref
Chuli Song, Tianyu Zhang & Yingjiu Zhang. (2022) Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42. Molecules 27:19, pages 6751.
Crossref
Dylan Shea & Valerie Daggett. (2022) Amyloid-β Oligomers: Multiple Moving Targets. Biophysica 2:2, pages 91-110.
Crossref
Mingchao Shi, Fengna Chu, Feiqi Zhu & Jie Zhu. (2022) Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience 14.
Crossref
Linda Giampietri, Elisabetta Belli, Maria Francesca Beatino, Sara Giannoni, Giovanni Palermo, Nicole Campese, Gloria Tognoni, Gabriele Siciliano, Roberto Ceravolo, Ciro De Luca & Filippo Baldacci. (2022) Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics 12:4, pages 796.
Crossref
Armando R. Irizarry Rovira, David Garcia-Tapia & Daniel J. Patrick. 2022. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology 1029 1076 .
Gustavo Alves Andrade dos Santos. 2022. Pharmacological Treatment of Alzheimer's Disease. Pharmacological Treatment of Alzheimer's Disease 1 14 .
Ae Young Lee. (2021) Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. Journal of the Korean Neurological Association 39:3, pages 134-140.
Crossref
Sarah F Ackley, Scott C Zimmerman, Willa D Brenowitz, Eric J Tchetgen Tchetgen, Audra L Gold, Jennifer J Manly, Elizabeth Rose Mayeda, Teresa J Filshtein, Melinda C Power, Fanny M Elahi, Adam M Brickman & M Maria Glymour. (2021) Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ, pages n156.
Crossref
Hana Na, Hua Tian, Zhengrong Zhang, Qiang Li, Jack B. Yang, Liam Mcparland, Qini Gan & Wei Qiao Qiu. (2021) Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer’s Disease in a Mouse Model. American Journal of Alzheimer's Disease & Other Dementiasr 36, pages 153331752110128.
Crossref
Dezerae Cox, Candice Raeburn, Xiaojing Sui & Danny M. Hatters. (2020) Protein aggregation in cell biology: An aggregomics perspective of health and disease. Seminars in Cell & Developmental Biology 99, pages 40-54.
Crossref
Seong Gak Jeon, Anji Yoo, Dong Wook Chun, Sang Bum Hong, Hyunju Chung, Jin-il Kim & Minho Moon. (2020) The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer’s Disease-related Pathogenesis. Aging and disease 11:3, pages 705.
Crossref
Angela Tian Hui Kwan, Saman Arfaie, Joseph Therriault, Pedro Rosa-Neto & Serge Gauthier. (2020) Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Dementia and Geriatric Cognitive Disorders 49:4, pages 334-348.
Crossref
P. Bali, A. Banik, B. Nehru & Akshay Anand. (2019) Neurotrophic Factors Mediated Activation of Astrocytes Ameliorate Memory Loss by Amyloid Clearance after Transplantation of Lineage Negative Stem Cells. Molecular Neurobiology 56:12, pages 8420-8434.
Crossref
Seong Gak Jeon, Sang Bum Hong, Yunkwon Nam, Jungyeon Tae, Anji Yoo, Eun Ji Song, Kun Il Kim, Dongje Lee, Junyong Park, Sang Min Lee, Jin-il Kim & Minho Moon. (2019) Ghrelin in Alzheimer’s disease: Pathologic roles and therapeutic implications. Ageing Research Reviews 55, pages 100945.
Crossref
Prashant Bharadwaj. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease 291 310 .
Daniel K. Burns, Carl Chiang, Kathleen A. Welsh‐Bohmer, Stephen K. Brannan, Meredith Culp, Janet O'Neil, Grant Runyan, Patrick Harrigan, Brenda L. Plassman, Michael Lutz, Eric Lai, Stephen Haneline, David Yarnall, Deborah Yarbrough, Craig Metz, Sridevi Ponduru, Scott Sundseth & Ann M. Saunders. (2019) The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5:1, pages 661-670.
Crossref
Hideki Mochizuki, Chi-Jing Choong & Eliezer Masliah. (2018) A refined concept: α-synuclein dysregulation disease. Neurochemistry International 119, pages 84-96.
Crossref
Biao Cheng, Yang Li, Liang Ma, Zhuoyi Wang, Robert B. Petersen, Ling Zheng, Yuchen Chen & Kun Huang. (2018) Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy. Biochimica et Biophysica Acta (BBA) - Biomembranes 1860:9, pages 1876-1888.
Crossref
D’Artagnan Greene, Theodora Po, Jennifer Pan, Tanya Tabibian & Ray Luo. (2018) Computational Analysis for the Rational Design of Anti-Amyloid Beta (Aβ) Antibodies. The Journal of Physical Chemistry B 122:16, pages 4521-4536.
Crossref
Isabelle L. Sumner, Ross A. Edwards, Ayodeji A. Asuni & Jessica L. Teeling. (2018) Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Frontiers in Neuroscience 12.
Crossref
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, Norbert Benda, Karl Broich, A. Claudio Cuello, Jeffrey Cummings, Bruno Dubois, Howard J. Federoff, Massimo Fiandaca, Remy Genthon, Marion Haberkamp, Eric Karran, Mark Mapstone, George Perry, Lon S. Schneider, Lindsay A. Welikovitch, Janet Woodcock, Filippo Baldacci & Simone Lista. (2018) Precision pharmacology for Alzheimer’s disease. Pharmacological Research 130, pages 331-365.
Crossref
Anne-Claire Dupont, Bérenger Largeau, Denis Guilloteau, Maria Joao Santiago Ribeiro & Nicolas Arlicot. (2018) The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. Contrast Media & Molecular Imaging 2018, pages 1-15.
Crossref
Abdelrahman Ibrahim Abushouk, Ahmed Elmaraezy, Amro Aglan, Reham Salama, Samar Fouda, Rana Fouda & Ammar M. AlSafadi. (2017) Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials. BMC Neurology 17:1.
Crossref
Haihao Zhu, Xiehua Xue, Erming Wang, Max Wallack, Hana Na, Jacob M. Hooker, Neil Kowall, Qiushan Tao, Thor D. Stein, Benjamin Wolozin & Wei Qiao Qiu. (2017) Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease. Neuropharmacology 119, pages 170-181.
Crossref
Akhlaq A. Farooqui. 2017. Neurochemical Aspects of Alzheimer's Disease. Neurochemical Aspects of Alzheimer's Disease 331 359 .
Yvonne Bouter, Jose Socrates Lopez Noguerola, Petra Tucholla, Gabriela A. N. Crespi, Michael W. Parker, Jens Wiltfang, Luke A. Miles & Thomas A. Bayer. (2015) Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathologica 130:5, pages 713-729.
Crossref
Anna Bogstedt, Maria Groves, Keith Tan, Rajesh Narwal, Mary McFarlane & Kina Höglund. (2015) Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. Journal of Alzheimer's Disease 46:4, pages 1091-1101.
Crossref
Andreas Soejitno, Anastasia Tjan & Thomas Eko Purwata. (2015) Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs 29:6, pages 487-502.
Crossref
Timothy M. Ryan, Blaine R. Roberts, Gawain McColl, Dominic J. Hare, Philip A. Doble, Qiao-Xin Li, Monica Lind, Anne M. Roberts, Haydyn D. T. Mertens, Nigel Kirby, Chi L. L. Pham, Mark G. Hinds, Paul A. Adlard, Kevin J. Barnham, Cyril C. Curtain & Colin L. Masters. (2015) Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. The Journal of Neuroscience 35:7, pages 2871-2884.
Crossref
V. Prakash Reddy. 2015. Organofluorine Compounds in Biology and Medicine. Organofluorine Compounds in Biology and Medicine 241 263 .
Gillian R. Langley. (2014) Considering a new paradigm for Alzheimer's disease research. Drug Discovery Today 19:8, pages 1114-1124.
Crossref
Eric Karran & John Hardy. (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annals of Neurology 76:2, pages 185-205.
Crossref
Hui Jin, Weixi Wang, Shanshan Zhao, Weina Yang, Yihua Qian, Ning Jia & Gaifeng Feng. (2014) Aβ-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Aβ deposit in PDAPP mice. Vaccine 32:35, pages 4450-4456.
Crossref
C. J. Lansdall. (2014) An effective treatment for Alzheimer's disease must consider both amyloid and tau. Bioscience Horizons 7:0, pages hzu002-hzu002.
Crossref
Andrew D. Watt, Gabriela A. N. Crespi, Russell A. Down, David B. Ascher, Adam Gunn, Keyla A. Perez, Catriona A. McLean, Victor L. Villemagne, Michael W. Parker, Kevin J. Barnham & Luke A. Miles. (2014) Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?. Acta Neuropathologica 127:6, pages 803-810.
Crossref
Francesco Panza, Giancarlo Logroscino, Bruno P. Imbimbo & Vincenzo Solfrizzi. (2014) Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry 27:2, pages 128-137.
Crossref
Dev Singh, Manish Gupta, Rajesh Kesharwani, Mamta Sagar, Seema Dwivedi & Krishna Misra. (2014) Molecular drug targets and therapies for Alzheimer’s disease. Translational Neuroscience 5:3.
Crossref
Hugo Vanderstichele & Thomas Kodadek. (2014) Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. Alzheimer's Research & Therapy 6:2, pages 23.
Crossref
Ramón Cacabelos, Pablo Cacabelos & Clara Torrellas. 2014. Handbook of Pharmacogenomics and Stratified Medicine. Handbook of Pharmacogenomics and Stratified Medicine 563 615 .
Ramón Cacabelos, Pablo Cacabelos, Clara Torrellas, Iván Tellado & Juan C. Carril. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development 323 556 .
Nady Braidy, Anne Poljak, Tharusha Jayasena & Perminder Sachdev. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity 1173 1190 .
Xenia Kobeleva & Susanne Petri. (2013) Barriers to novel therapeutics in amyotrophic lateral sclerosis. Neurodegenerative Disease Management 3:6, pages 525-537.
Crossref
Sandra Sivilia, Luca Lorenzini, Alessandro Giuliani, Marco Gusciglio, Mercedes Fernandez, Vito Antonio Baldassarro, Chiara Mangano, Luca Ferraro, Vladimiro Pietrini, Maria Francesca Baroc, Arturo R Viscomi, Simone Ottonello, Gino Villetti, Bruno P Imbimbo, Laura Calzà & Luciana Giardino. (2013) Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neuroscience 14:1.
Crossref
Jens Pahnke, Christina Fröhlich, Markus Krohn, Toni Schumacher & Kristin Paarmann. (2013) Impaired mitochondrial energy production and ABC transporter function—A crucial interconnection in dementing proteopathies of the brain. Mechanisms of Ageing and Development 134:10, pages 506-515.
Crossref
Camryn Berk & Marwan N. Sabbagh. (2013) Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease. Drugs & Aging 30:10, pages 783-792.
Crossref
Shermali Gunawardena. (2013) Nanoparticles in the Brain: A Potential Therapeutic System Targeted to an Early Defect Observed in Many Neurodegenerative Diseases. Pharmaceutical Research 30:10, pages 2459-2474.
Crossref
Patrick L. McGeer & Edith G. McGeer. (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathologica 126:4, pages 479-497.
Crossref
Pavan Kumar, Zoltan Dezso, Crystal MacKenzie, Judy Oestreicher, Sergei Agoulnik, Michael Byrne, Francois Bernier, Mamoru Yanagimachi, Ken Aoshima & Yoshiya Oda. (2013) Circulating miRNA Biomarkers for Alzheimer's Disease. PLoS ONE 8:7, pages e69807.
Crossref
Adnan Nasir & Anthony Gaspari. 2013. Nanotechnology in Dermatology. Nanotechnology in Dermatology 151 164 .
Andrew F. TeichOttavio Arancio. (2012) Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. Biochemical Journal 446:2, pages 165-177.
Crossref
Francesco PanzaVincenza Frisardi, Bruno P Imbimbo, Giancarlo Logroscino, Davide Seripa, Alberto Pilotto & Vincenzo Solfrizzi. (2012) Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients. Future Neurology 7:4, pages 395-401.
Crossref
Michiko Konno. (2012) Treatment of Dementias: Current Approaches and Disease Modifying Drugs. Journal of Nihon University Medical Association 71:6, pages 379-384.
Crossref
Hugo Vanderstichele, Erik Stoops, Eugeen Vanmechelen & Andreas Jeromin. (2012) Potential sources of interference on Abeta immunoassays in biological samples. Alzheimer's Research & Therapy 4:5, pages 39.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.